For six years, the size of the BPC-157 market has been an educated guess. Vendor traffic, forum volume and search interest all pointed the same direction, but none of them counted people. On September 16, 2026, Reuters carried the first analysis that did: the data analytics firm nference searched more than 15 million de-identified medical records and found 1,039 patients whose physicians had typed BPC-157 into a clinical note by hand.
The headline number is that new documented users rose 33-fold between 2020 and 2026. The more interesting numbers are underneath it — the user got younger, got more male, and increasingly showed up for pain and gut complaints rather than sports injuries alone. The report was posted to Preprints.org ahead of peer review, and its authors are explicit that 1,039 is a floor rather than a population estimate.
Research-context information only. This article reports on a pre-peer-review data analysis and the news coverage of it. It is not medical advice, and nothing here is a recommendation to use, dose or discontinue any compound. BPC-157 is sold in the research channel as research-use-only material, is not approved by the FDA for human use, and has not been evaluated for safety, purity or potency as sold in that channel. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.
What the analysis found
| Element | Detail |
|---|---|
| Analyst | nference (data analytics firm), led by Venky Soundararajan |
| Status | Report posted to Preprints.org ahead of peer review, September 2026 |
| Records searched | 15,000,000+ de-identified medical records |
| Patients identified | 1,039 with BPC-157 documented in clinical notes |
| Reason for use recorded | 644 patients |
| Growth in new users | 33-fold, 2020 to 2026 |
| Male share of new users | 57% (2020) to 70% (2026) |
| Mean age of new users | 55 (2020) to 49 (2026) |
| Race recorded | 972 patients; 96% white |
| Treatment response documented | roughly one-third of patients |
| FDA adverse event reports | 10 since 2021, 8 of them in 2026 |
Three things carry the paper.
The method is the finding. BPC-157 has no National Drug Code. Every automated query that health systems run against their own prescribing data is keyed to that identifier, which means a compound bought outside the pharmacy system is structurally invisible to the tooling researchers normally use. The only way to count it is to read what a clinician wrote in free text — and that only happens when a patient volunteers it and the clinician records it. Study leader Venky Soundararajan put the gap plainly to Reuters: "Most likely, very few doctors are even asking their patients, 'Are you taking BPC-157?'"
The demographic drift is the real signal. A 33-fold rise in raw count could be an artefact of clinicians learning to ask. A simultaneous shift in who shows up is harder to explain that way. Male share climbing from 57% to 70% while mean age drops from 55 to 49 describes a compound migrating out of a longevity-clinic patient base and into a performance and recovery one — which is precisely the audience the research channel has been selling to, and it is the first time that migration has been measured in medical records rather than inferred from vendor catalogues.
The reasons are broader than the marketing. Of the 644 patients with a documented reason, use spanned sports injuries, chronic pain and gastrointestinal disorders. That gut-facing share matters, because BPC-157 originated in gastrointestinal research and most of its published animal work concerns gut and vascular models — the tendon-and-ligament framing that dominates the consumer market is the newer application, not the older one.
The "Wolverine peptide" label is doing some work
Every wire headline on this story called BPC-157 the "Wolverine peptide." The analysis did not — it looked at BPC-157 alone.
That distinction is worth holding, because in the research channel "Wolverine" almost always refers to the BPC-157 and TB-500 combination, sold as a pre-mixed blend and dosed as a pair. The nference data cannot separate people running BPC-157 on its own from people running it inside that stack, because the clinical notes it read were written by physicians recording what a patient mentioned, not by anyone reconstructing a protocol.
The practical consequence: the 33-fold figure is a floor for BPC-157 specifically, and the real-world figure for the blend is unmeasured. Our Wolverine stack overview covers how the two compounds are actually combined and where their evidence bases diverge.
What this does and does not change for buyers
It changes nothing about supply. This is an observational data paper, not an enforcement action. No vendor is affected, no listing comes down, and pricing and stock are unmoved. That is a meaningful distinction from the five FDA warning letters posted on September 1, which did change what specific sellers list.
It changes the quality of the conversation with a physician. The single most actionable line in the paper is the observation that clinicians largely are not asking. A patient who volunteers the information is now volunteering it into a documented pattern rather than a vacuum — there is a real-world dataset, however thin, describing 1,039 people who did the same. Ten adverse event reports across six years is a low absolute number against 33-fold growth, but eight of those ten landing in 2026 alone is the kind of trend a treating physician would reasonably want the context for.
It does not answer whether the compound works. Responses to treatment were recorded for only about a third of patients, and where notes described improvement there is no control, no blinding and no way to separate the compound from natural recovery, concurrent treatment or selective documentation. The paper is a census, not a trial. For what the controlled literature does and does not show, our BPC-157 clinical trials tracker covers the registered human studies, and last week's UCLA scoping review of 565 studies covers the published evidence base and its 67% preclinical share.
It sharpens one comparison worth watching. The first properly controlled human outcome data on BPC-157 is now in progress rather than hypothetical — the rotator cuff surgery trial and a registered acute hamstring strain study both read out over the next 12 to 18 months. A real-world usage census landing just before those trials means the exposure baseline is on record before the efficacy answer arrives, which is unusual and useful.
